Editorial

Developing the Next Generation of Clinically Successful Antibody-drug Conjugates

Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers...

Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament

Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in...

The Challenge of Antibody-drug Conjugates (ADC) Characterization

Therapeutic antibody–drug conjugates or ADCs (also known as immunoconjugates) selectively kill tumor cells that overexpress a specific target antigen...

How Personalization Will Improve Healthcare

While healthcare reform has many challenges, there are some very positive things happening behind the scenes. One of them...

CPhI Worldwide 2015, Antibody-drug Conjugates and Market Progression

Ahead of CPhI Worldwide 2015, CPhI expert panelist, Vivek Sharma, CEO of Pharma Solutions at Piramal, analyses the challenges...

Event Preview: CPhI Worldwide 2015

CPhI Worldwide 2015 returns to Madrid, Spain, for the 26th edition, bringing with it the booming pharmaceutical industry ready...

New Anticancer Drugs Show Promise in the Treatment of Solid Tumors

A number of novel anticancer drugs are showing very promising results in the treatment of solid cancers. These cancers, including...

What to Expect at ASCO 2015?

The 51st ASCO - the Annual Meeting of the American Society of Clinical Oncology, which will take place in the McCormick Place Convention Center in Chicago, Illinois, May 29 – June 2, 2015 is expected attract more than 30,000 oncology professionals from around the world.

Investigational ADC Shows Promise for Patients with Metastatic HER2-positive Breast Cancer

Data from a Phase I clinical trial of MM-302 (Merrimack Pharmaceuticals) presented at the annual meeting of the American...

Developing a New BiTe against Acute Myeloid Leukemia

Astellas Pharma Inc. (Tokyo, Japan) and The University of Texas MD Anderson Cancer Center (Houston, Texas) have signed an option...